Stent implantation, but not pathogen burden, is associated with plasma C-reactive protein and interleukin-6 levels after percutaneous coronary intervention in patients with stable angina pectoris

Am Heart J. 2005 May;149(5):876-82. doi: 10.1016/j.ahj.2004.07.039.

Abstract

Background: The systemic inflammatory response to percutaneous coronary intervention (PCI) is associated with recurrent cardiac events; however, the pathophysiology of this inflammatory response is not well understood. The present study was performed to investigate the role of pathogen burden of infection in determining the magnitude of C-reactive protein (CRP) and interleukin 6 (IL-6) response to PCI.

Methods: One hundred patients with stable angina pectoris undergoing elective PCI at a single center were recruited. Antibodies against cytomegalovirus, Chlamydia pneumoniae , Epstein-Barr virus, Helicobacter pylori , and herpes simplex virus types 1 and 2 were determined before PCI. Plasma CRP and IL-6 levels were measured before and 6, 24, 48, 72 hours after PCI and data presented as area under the curve.

Results: Plasma CRP and IL-6 concentrations increased significantly after PCI. Neither antibodies against single nor multiple pathogens were associated with the CRP or IL-6 response to PCI. No correlations were found between the inflammatory markers and troponin T levels after PCI. With the exception for CRP and body mass index (R = 0.20, P < .05), neither risk factors for coronary heart disease nor medication but stent implantation was associated with increased plasma CRP (76 vs 61 mg/L, P < .005) and IL-6 (74 vs 64 pg/mL, P < .005) levels after PCI.

Conclusion: Stent implantation, but not pathogen burden, is associated with the plasma CRP and IL-6 response to PCI.

MeSH terms

  • Aged
  • Angina Pectoris / blood*
  • Angina Pectoris / microbiology*
  • Angina Pectoris / therapy
  • Angioplasty, Balloon, Coronary / adverse effects*
  • Area Under Curve
  • C-Reactive Protein / metabolism*
  • Coronary Restenosis / etiology
  • Female
  • Humans
  • Interleukin-6 / blood*
  • Male
  • Middle Aged
  • Prospective Studies
  • Stents / adverse effects*
  • Troponin T / blood

Substances

  • Interleukin-6
  • Troponin T
  • C-Reactive Protein